Surprisingly, recent large-scale cardiovascular safety trials demonstrate that SGLT2 inhibitors exert not only antidiabetic actions but also cardioprotective effects (Zelniker and Braunwald, 2020)and the use of SGLT2 inhibitors in patients with diabetes mellitus (DM), chronic kidney disease (CKD), and heart failure (HF) to reduce related cardiac complications and comorbidities of cardiac arrhythmias (Li et al., 2021). This evidence concerns the gene SLC5A2 and chronic obstructive pulmonary disease.